Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Research output: Contribution to journalReviewResearchpeer-review

  1. A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reply to: "Seasonal variations of lipid profiles in a French cohort"

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 18F-FDG PET/MR-imaging in a Göttingen Minipig model of atherosclerosis: Correlations with histology and quantitative gene expression

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Obesity as a Causal Risk Factor for Aortic Valve Stenosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Incidental lymphopenia and mortality: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative
View graph of relations

The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (=total - HDL cholesterol) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDL cholesterol is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDL cholesterol shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a)-cholesterol is part of measured or calculated LDL cholesterol and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDL cholesterol decline poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDL cholesterol or apolipoprotein B, especially in patients with mild-to-moderate hypertriglyceridemia (2-10 mmol/L). Non-HDL cholesterol includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apolipoprotein B measurement can detect elevated LDL particle numbers often unidentified on the basis of LDL cholesterol alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20-100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds.

Original languageEnglish
JournalAtherosclerosis
Volume294
Pages (from-to)46-61
Number of pages16
ISSN0021-9150
DOIs
Publication statusPublished - Feb 2020

    Research areas

  • Apolipoprotein B, Atherosclerotic cardiovascular disease, LDL cholesterol, Lipoprotein(a), non-HDL cholesterol, Remnant cholesterol

ID: 59348936